

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/SDD/2022-23

Date- 17.11.2022

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai- 400001

National Stock Exchange of India Ltd

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

Code No- 531146

Code No. MEDICAMEQ

Sub: SDD Compliance Certificate for the Quarter ended September 30, 2022

Dear Sir/Madam,

Pursuant to Regulation 3(5) and 3(6) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, please find attached herewith the SDD Compliance Certificate for the Quarter ended September 30, 2022.

This is for your information and records

Kindly acknowledge the receipt of the same.

Thanking you,

Yours faithfully

For **Medicamen Biotech Limited**

Parul Choudhary

Company Secretary & Compliance Officer

ACS- 44157

COMPLIANCE CERTIFICATE FOR THE QUARTER ENDED SEPTEMBER 2022

(Pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015)

I, Parul Choudhary, Compliance Officer, have examined the following compliance requirement of Medicamen Biotech Limited (Company) and certify that the Company has maintained a Structured Digital Database (SDD) pursuant to provisions of Regulation 3(5) and 3(6) of **Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015** (PIT Regulations):

Sr. No	Compliance Requirement	Yes/No	Observation/ Remark
1.	Whether the Company has a Structured Digital Database in place?	Yes	The Company has its Structured Digital Database
2.	Whether control exists as to who can access the SDD for read/ write along with the names and PAN of such person?	Yes	Absolute control exists as the Name and PAN of the Persons who have access to the Structured Digital Database is captured in the system
3.	Whether all the UPSI had been captured in the Database. If not details of events that had not been captured and the reason for the same?	Yes	The Company has captured all the events of Unpublished Price Sensitive Information (UPSI)
4.	Whether the recipients were upfront informed that the information which they will be receiving shortly is UPSI and the entry has been captured in the Database prior to forwarding the UPSI data. If not details of events that have not been captured and the reason for the same?	Yes	The recipients were upfront informed that the information is UPSI and the entry has been captured in the Database, prior to forwarding of the UPSI Data.
5.	Whether nature of UPSI have been captured along with date and time?	Yes	We have captured the data with the date and time
6.	Whether name of persons who have shared the information has been captured along with PAN or any other identifier?	Yes	The name of persons who have shared the information has been captured along with the PAN
7.	Whether name of persons with whom information is shared has been captured along with PAN or any other identifier?	Yes	The name of persons with whom the information has been shared, has been captured along with the PAN
8.	Whether the database has been maintained internally?	Yes	Database is maintained internally
9.	Whether audit trail is maintained?	Yes	The Company has maintained the Audit Trail

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

10.	Whether time stamping is maintained?	Yes	The Company has maintained the Time Stamping
11.	Whether the database is non-tamperable?	Yes	The Database is non – tamperable. Adequate measures are taken to protect the same with limited access to the designated people only.
12.	Any other measures to ensure non-tamperability of the Database?	Yes	Access is only available with the designated officials. Hence, the Company ensures non tamperability of the data.

Note: The information of the audit should cover the period when such information was inserted in the SDD up to the date of disclosure.

The number of days for which non-compliance was observed: Nil

Further I also confirm that the Company was required to capture Nil number of events during the quarter ended September 30, 2022 and has captured Nil number of the said required events.

For **Medicamen Biotech Limited**

Parul Choudhary
Company Secretary & Compliance Officer
ACS: 44157

Date: 17.11.2022
Place: New Delhi